Nazarin Cibiyoyin Daban-daban Ya Nuna Kyakkyawan Hasashe Ga Marasa Lafiyar Jini Da Ke Yin Dashen Kwayoyin Halittar Allogeneic Tare Da ATG
Wani bincike da aka gudanar a cibiyoyi da dama a kasar Sin ya nuna kyakkyawan sakamako na dashen ƙwayoyin halittar jini marasa alaƙa (MMUD) allogeneic hematopoietic stem cell (allo-HSCT) ga marasa lafiya da ke fama da cutar kansar jini. An buga a Dashen Maƙogwaro na Kashi, wannan binciken ya binciki ingancin haɗa MMUD allo-HSCT tare da antithymocyte globulin (ATG) don hana cutar graft-versus-host (GVHD). Wannan hanyar ta nuna cewa tana samar da sakamako mai ƙarfi na asibiti, koda tare da rashin daidaito a cikin jituwa tsakanin antigen leukocyte na ɗan adam (HLA) tsakanin mai bayarwa da mai karɓa.
Binciken ya yi rijistar marasa lafiya 211 masu shekaru 14 ko sama da haka, waɗanda aka gano suna da cutar kansar jini kuma an yi musu magani gaba ɗaya kafin a yi musu dashen. An raba marasa lafiya zuwa ƙungiyoyi biyu bisa ga adadin rashin daidaiton HLA: Rukunin A tare da rashin daidaiton allele ɗaya da Rukunin B tare da rashin daidaito biyu ko fiye. Duk marasa lafiya sun sami ƙwayoyin halittar jini na gefe da kuma maganin kwantar da hankali tare da tsarin share maƙogwaro, tare da rigakafin GVHD wanda ya haɗa da ATG.
Babban sakamakon ya haɗa da yawan tarawar ƙwayoyin cuta na kashi 96.2% ga neutrophils da kashi 93.4% ga ƙwayoyin cuta a cikin kwanaki 28 na farko. Binciken ya kuma nuna ƙarancin yawan kamuwa da cutar GVHD mai tsanani, inda GVHD na mataki na III-IV ya faru a cikin kashi 12.3% na lokuta, da kuma GVHD na yau da kullun mai matsakaici zuwa mai tsanani ya kai kashi 21% bayan shekaru uku. Jimlar yawan rayuwa (OS) na shekaru uku shine kashi 63.1%, tare da ƙimar rayuwa ba tare da cututtuka ba (DFS) shine kashi 54.5%.
Binciken ya kuma nuna cewa adadin rashin daidaiton HLA bai yi tasiri sosai ga yawan rayuwa ba, yawan kamuwa da cutar GVHD, ko sake kunna kwayar cutar. Bugu da ƙari, amfani da ƙananan allurai na ATG (≤6 mg/kg) ya inganta yawan aikin gyaran fuska kuma ya ba da fa'idodi na asibiti ba tare da yin tasiri ga rayuwa ko sake dawowa ba, yana ba da zaɓin magani mai araha.
Wannan bincike shine babban bincike da aka gudanar a wurare da dama a kasar Sin kan MMUD allo-HSCT kuma ya nuna yuwuwar wannan hanyar dashen ga marasa lafiya da ke dauke da cutar kansar jini mai hatsari. Yana bayar da bayanai masu mahimmanci game da inganta sakamakon marasa lafiya da kuma inganta ka'idojin dashen, wanda hakan ya sanya shi muhimmiyar gudummawa ga fannin jini. Maganin Ciwon daji.